Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Oxbryta
Pharma
Pfizer pulls sickle cell disease drug Oxbryta from global markets
The market withdrawal is a blow to Pfizer's $5.4 billion acquisition of Global Blood Therapeutics in 2022.
Angus Liu
Sep 25, 2024 6:00pm
J&J lost to Pfizer in $5.4B GBT bidding war: Bloomberg
Aug 24, 2022 10:15am
How Pfizer became interested in GBT and reached the $5.4B buy
Aug 23, 2022 10:50am
Pfizer scoops up Global Blood Therapeutics for $5.4B
Aug 8, 2022 7:56am
GBT sickle cell campaign agency launches pharma comms division
Oct 20, 2021 10:46am
GBT debuts first DTC campaign for sickle cell med Oxbryta
Jul 30, 2021 10:58am
